Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse‐deterrent controlled‐release tablets in recreational opioid users
Open Access
- 11 December 2013
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 54 (4) , 468-477
Abstract
The objective of this study was to evaluate abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered, crushed reformulated OxyContin® (oxycodone HCl controlled‐release) tablets (ORF), relative to crushed original OxyContin® (OC), oxycodone powder (Oxy API), and OC placebo. This randomized, double‐blind, positive‐ and placebo‐controlled crossover study enrolled healthy, adult, nonphysically dependent recreational opioid users with recent history of intranasal drug abuse (N = 27). Active treatments contained oxycodone (30 mg). Pharmacokinetics, pharmacodynamics (e.g., Overall Drug Liking [ODL], Take Drug Again [TDA], and High Visual Analog Scales [VAS]; Subjective Drug Value [SDV]; pupillometry; intranasal irritation), and safety (e.g., adverse events, vital signs, laboratory tests) were assessed to 24 hours postdose. Crushed ORF administration yielded reduced oxycodone Cmax and increased Tmax versus crushed OC and Oxy API. Peak effects for pharmacodynamic measures were delayed with ORF (1–2 hours) versus OC and Oxy API (0.5–1 hour). ODL, TDA, High VAS, and SDV Emax values were significantly lower (P ≤ .05) and some intranasal irritation ratings were greater for ORF versus OC and Oxy API. No significant or unexpected safety findings were observed. Compared with OC and Oxy API, intranasally administered ORF was associated with lower and delayed peak plasma concentrations, decreased drug‐liking, and decreased intranasal tolerability. This suggests that ORF has a decreased potential for intranasal oxycodone abuse. There were no significant or unexpected safety findings. As is true for all abuse potential studies, epidemiological or other appropriate post‐marketing studies are required to assess the impact of the reduction in intranasal oxycodone abuse potential observed in the present study on real‐world patterns of ORF misuse, abuse, and diversion.Keywords
This publication has 25 references indexed in Scilit:
- A comparison of the street price of original and reformulated OxyContin® and immediate release (IR) oxycodone productsThe Journal of Pain, 2012
- Tampering with Prescription Opioids: Nature and Extent of the Problem, Health Consequences, and SolutionsThe American Journal of Drug and Alcohol Abuse, 2011
- Abuse risks and routes of administration of different prescription opioid compounds and formulationsHarm Reduction Journal, 2011
- Route of administration for illicit prescription opioids: a comparison of rural and urban drug usersHarm Reduction Journal, 2010
- Abuse-Deterrent and Tamper-Resistant Opioid FormulationsCNS Drugs, 2010
- Trends in Abuse of OxyContin® and Other Opioid Analgesics in the United States: 2002-2004The Journal of Pain, 2005
- The Pharmacokinetics of OxycodoneJournal of Pain & Palliative Care Pharmacotherapy, 2005
- The Pharmacokinetics of OxycodoneJournal of Pain & Palliative Care Pharmacotherapy, 2005
- Route of drug use and its implications for drug effect, risk of dependence and health consequencesDrug and Alcohol Review, 1998
- Validation of the multiple-choice procedure for investigating drug reinforcement in humans.Experimental and Clinical Psychopharmacology, 1996